104 related articles for article (PubMed ID: 2701727)
21. Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia.
Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():63. PubMed ID: 2496883
[No Abstract] [Full Text] [Related]
22. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.
Claxton D; Deisseroth A; Talpaz M; Reading C; Kantarjian H; Trujillo J; Stass S; Gooch G; Spitzer G
Blood; 1992 Feb; 79(4):997-1002. PubMed ID: 1371081
[TBL] [Abstract][Full Text] [Related]
23. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
Bergsagel DE; Messner H
Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
[TBL] [Abstract][Full Text] [Related]
24. Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients.
Ferrajoli A; Liberati AM; Caricchi P; Donti E; Morra E; Lazzarino M; Betti AR; Bernasconi P; Saglio G
Eur J Haematol; 1995 Sep; 55(3):184-8. PubMed ID: 7672091
[TBL] [Abstract][Full Text] [Related]
25. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
[TBL] [Abstract][Full Text] [Related]
26. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
27. Activity of alpha-interferons in chronic myelogenous leukaemia.
Talpaz M
Br J Clin Pract Suppl; 1988 Mar; 62():13-5. PubMed ID: 3145008
[No Abstract] [Full Text] [Related]
28. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation.
Bartsch HH; Pfizenmaier K; Hanusch A; Scheurich P; Ucer U; Nagel GA
Int J Cancer; 1989 Feb; 43(2):235-40. PubMed ID: 2521842
[TBL] [Abstract][Full Text] [Related]
29. Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon.
Talpaz M; Trujillo JM; Hittelman WN; Keating MJ; Gutterman JU
Br J Haematol; 1985 Aug; 60(4):619-24. PubMed ID: 3861194
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
31. [The treatment of chronic myeloid leukemia in chronic phase with interferons].
Guilhot F
Pathol Biol (Paris); 1988 Dec; 36(10):1179-81. PubMed ID: 3070457
[No Abstract] [Full Text] [Related]
32. Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
Cancer; 1992 Jan; 69(2):410-2. PubMed ID: 1370212
[TBL] [Abstract][Full Text] [Related]
33. [The treatment of chronic myeloleukemia with recombinant alfa-2 interferon].
Strozha I; Petukhov V; Bondare D; Feldmane G; Duks A; Teilane I; Medne I; Mauritsas M; Grinberga L
Ter Arkh; 1993; 65(10):62-6. PubMed ID: 8296238
[TBL] [Abstract][Full Text] [Related]
34. Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia.
Claxton D; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU; Talpaz M
Acta Haematol; 1990; 83(3):149-51. PubMed ID: 2109455
[TBL] [Abstract][Full Text] [Related]
35. Juvenile chronic myeloid leukaemia and alpha-interferon.
Aricò M; Nespoli L; Caselli D; Bonetti F; Porta FA; Burgio GR
Eur J Pediatr; 1989 Jan; 148(4):379-80. PubMed ID: 2707286
[No Abstract] [Full Text] [Related]
36. CML: new biologic therapies, endpoints and questions.
Martin A; Cheson BD
Oncology (Williston Park); 1987 Sep; 1(7):12-3, 16. PubMed ID: 3152809
[No Abstract] [Full Text] [Related]
37. Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase.
Wahlin A; Holm J; Engman K
Acta Oncol; 1991; 30(5):611-5. PubMed ID: 1892679
[TBL] [Abstract][Full Text] [Related]
38. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.
Schilling PJ; Kurzrock R; Kantarjian H; Gutterman JU; Talpaz M
Cancer; 1991 Oct; 68(7):1536-7. PubMed ID: 1893353
[TBL] [Abstract][Full Text] [Related]
39. Interferon and chronic myelogenous leukaemia.
Lauta VM
Med Oncol; 1995 Mar; 12(1):41-6. PubMed ID: 8542246
[TBL] [Abstract][Full Text] [Related]
40. Biotherapy of chronic myelogenous leukemia with interferon.
Ozer H
Semin Oncol; 1988 Oct; 15(5 Suppl 5):14-20. PubMed ID: 2461592
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
